Drug intelligence / Profile preview

LBI-002

Development stage: Preclinical
Lead developer: Longevity Biomedical
Administration: Surgical, Implantation, Ophthalmic, Intraocular

Overview

LBI-002 is a biosynthetic cornea developed as a replacement product for human corneal tissue. It is designed to mimic the optical properties of natural human corneas, support nerve regeneration, and promote epithelial growth. The product aims to address the significant unmet need in the treatment of corneal blindness and damage, potentially eliminating or reducing the need for donor tissue transplantation. Its development targets patients with conditions requiring corneal replacement due to injury or disease[1][2][3].

Beyond the preview

Go deeper on LBI-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBI-002.

Explore the full profile